Effect of Weight Loss on Hepcidin Levels and Iron Status in Subjects With Obesity.

Obesity Clinical Trial

Official title:

Effect of Weight Loss on Hepcidin Levels and Iron Status in Subjects With Obesity.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06104800
• Other study ID #: FNU-4686-23-24-1
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 8, 2024
• Est. completion date: December 30, 2024

Study information

• Verified date: October 2023
• Source: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Contact: Martha Guevara-Cruz, MD, PhD
• Phone: 54870900
• Email: marthaguevara8[@]yahoo.com.mx
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obesity and iron deficiency are the nutritional disorders with the highest prevalence worldwide. Different mechanisms have been proposed to explain iron deficiency secondary to obesity. Among the most studied is the deficit in dietary iron intake or the increase in blood volume that increases the need for the metal. However, one of the most plausible mechanisms linking obesity and iron deficiency is low-grade systemic inflammation, through the iron metabolism intermediate known as hepcidin. The investigators objective is to evaluate the effect of weight loss by caloric restriction on hepcidin and serum iron concentration in people living with obesity and iron deficiency. The study will be divided into two phases: Phase 1: A cross-sectional study (cases and controls) to compare hepcidin levels, iron status and inflammatory markers in people living with and without obesity. The second phase consists of an open-label randomized controlled clinical trial. Individuals living with obesity who are iron deficient will be recruited and randomized to one of 2 dietary intervention groups with 60-day follow-up. The intervention groups will be: diet with caloric restriction rich in protein (with red meat) and diet with caloric restriction rich in protein (without red meat). Hepcidin levels, iron status and inflammatory markers will be determined at the beginning and end of the intervention. The nutritional intervention will have the following distribution of macronutrients in the diet: protein 1.5 g/kg of ideal weight, 50% carbohydrates and 25-30% fats.

Description:

The study will consist of two phases: Phase 1, which will be cross-sectional, and Phase 2, which will involve a randomized controlled clinical trial.

Phase 1: Cross-Sectional Study A cross-sectional study will be conducted to compare hepcidin levels, iron status and inflammatory markers in people living with and without obesity. Upon obtaining signed consent, participants will undergo a medical history assessment, anthropometric measurements (weight, height, waist circumference), body composition analysis (% body fat, % skeletal muscle mass, % fat-free mass), and blood samples will be collected to determine serum hepcidin levels, iron status, inflammatory markers (C-reactive protein, interleukin-6, lipopolysaccharides), and oxidative stress markers (MDA).

Additional blood samples will be taken for biochemical tests (glucose, lipid profile, creatinine, urea, liver function tests), insulin, leptin, adiponectin, and, optionally, DNA isolation for polymorphisms determination and those associated with iron metabolism and obesity. Participants will also complete a food frequency questionnaire (SNUT).

Phase 2: Open randomized controlled clinical trial This phase will be conducted to assess the impact of weight loss on hepcidin levels, iron status, and inflammatory markers in individuals living with obesity. Participants recruited for this phase will be selected from those identified in the first phase who exhibit iron deficiency (serum iron < 50 mcg/dL).

Participants will be randomly assigned to one of two dietary intervention groups, both of which will undergo a 60-day follow-up period with a calorie-restricted diet, reducing caloric intake by less than 25% of the resting energy expenditure determined by indirect calorimetry. The intervention groups will be as follows:

• Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.

• Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats.

Additionally, all participants will receive ferrous sulfate 200mg every 48 hours for three months to correct iron-deficiency anemia.

During the initial and final visits, participants will undergo a 24-hour dietary recall, complete a physical activity questionnaire, and fill out a quality-of-life questionnaire. Additionally, anthropometric measurements and body composition analysis will be conducted. Blood samples will be collected to determine various biochemical parameters in the blood, including lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), liver function tests, glucose, insulin, creatinine, urea, oxidative stress markers, inflammatory markers (C-reactive protein and lipopolysaccharides), and iron status markers. Furthermore, stool samples will be collected to analyze the composition of the intestinal microbiota and metabolomics.

To assess treatment adherence, participants will be provided with a food logs to record their daily food consumption during the initial visit. The participants will also receive a pantry containing protein-rich foods every week to facilitate the nutritional intervention. Also, 2 phone calls will be made each week to evaluate adherence to treatment. The adherence will be determined with the % of adherence to the dietary treatment as obtained in the analysis of the food logs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 42
• Est. completion date: December 30, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Phase 1

• Signing of the informed consent form

• Both sexes

• Adults over 18 years of age

• BMI of 18.5 and under 40 kg/m2

Phase 2

• Both sexes

• Adults older than 18 years

• People with obesity (BMI of 30 to 40 kg/m2) and serum iron < 50 micrograms/dL.

• Total cholesterol less than 240 mg/dL (with the diet plan 20% decrease).

Exclusion Criteria:

• Any type of diabetes.

• Patients with renal disease diagnosed by a physician.

• Patients with acquired diseases that secondarily produce obesity and diabetes.

• Patients who have suffered a cardiovascular event.

• Weight loss > 3 kg in the last 3 months.

• Patients with catabolic diseases such as cancer and acquired immunodeficiency syndrome.

• Pregnancy.

• Treatment with any drug treatment:

1. Treatment with antihypertensive drugs (loop or potassium-sparing diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers, alpha blockers, calcium antagonists, beta blockers).

2. Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or insulin and antidiabetics.

3. Treatment with statins, fibrates or other drugs to control dyslipidemia.

4. Use of steroid drugs, chemotherapy, immunosuppressants or radiotherapy.

5. Anorectics or drugs that accelerate weight loss.

6. Any drug or medication that activates intestinal motility (cisapride, dimethicone, domperidone, metoclopramide, trimebutine).

7. Laxatives or antispasmodics 4 weeks prior to the study h) Antibiotic treatment 2 months prior to the study.

• Patients who have suffered a blood loss of more than 500 ml or recent gastrointestinal tract perforation.

• Patients with a smoking index greater than 21.

• Consumption of large amounts of alcohol (14 drinks for women or 21 drinks for men in a normal week).

• Consumption of any recreational psychoactive substance.

• Treatment with any medication that influences inflammation or iron metabolism (proton pump inhibitors, antacids, bisphosphonates, bile acid or calcium sequestrants).

• Patients who are vegetarians

• Allergy or intolerance to any food mentioned in the proposed pantry such as egg, dairy, fish, tuna, chicken, beans, lima beans and/or lentils.

• Unwillingness to consume any of the foods listed in the proposed pantry.

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Iron Deficiency Anemia
• Obesity
• Weight Loss

Intervention

Other:
• Calorie-restricted diet with red meat
Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
• Calorie-restricted diet without red meat
Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

References & Publications (22)

Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164-74. — View Citation

Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014;2014:730827. doi: 10.1155/2014/730827. Epub 2014 Apr 14. — View Citation

Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1559S-1566S. doi: 10.3945/ajcn.117.155804. Epub 2017 Oct 25. — View Citation

Becker C, Schumann K. Iron-homeostasis and obesity. J Trace Elem Med Biol. 2015 Apr;30:194. doi: 10.1016/j.jtemb.2014.06.009. Epub 2014 Jun 27. No abstract available. — View Citation

Cao C, Thomas CE, Insogna KL, O'Brien KO. Duodenal absorption and tissue utilization of dietary heme and nonheme iron differ in rats. J Nutr. 2014 Nov;144(11):1710-7. doi: 10.3945/jn.114.197939. Epub 2014 Sep 10. — View Citation

Chiabrando D, Vinchi F, Fiorito V, Mercurio S, Tolosano E. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol. 2014 Apr 8;5:61. doi: 10.3389/fphar.2014.00061. eCollection 2014. — View Citation

Coimbra S, Catarino C, Santos-Silva A. The role of adipocytes in the modulation of iron metabolism in obesity. Obes Rev. 2013 Oct;14(10):771-9. doi: 10.1111/obr.12057. Epub 2013 Jul 11. — View Citation

Collins JF, Wessling-Resnick M, Knutson MD. Hepcidin regulation of iron transport. J Nutr. 2008 Nov;138(11):2284-8. doi: 10.3945/jn.108.096347. — View Citation

Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017 Jun;21 Suppl 1(Suppl 1):S6-S20. doi: 10.1111/hdi.12542. Epub 2017 Mar 15. — View Citation

Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GJ. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology. 2002 Sep;123(3):835-44. doi: 10.1053/gast.2002.35353. — View Citation

Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, Cefalu WT, McClain DA. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012 Oct;122(10):3529-40. doi: 10.1172/JCI44421. Epub 2012 Sep 10. — View Citation

Joffin N, Gliniak CM, Funcke JB, Paschoal VA, Crewe C, Chen S, Gordillo R, Kusminski CM, Oh DY, Geldenhuys WJ, Scherer PE. Adipose tissue macrophages exert systemic metabolic control by manipulating local iron concentrations. Nat Metab. 2022 Nov;4(11):1474-1494. doi: 10.1038/s42255-022-00664-z. Epub 2022 Nov 3. — View Citation

Mejia-Rodriguez F, Villalpando S, Shamah-Levy T, Garcia-Guerra A, Mendez-Gomez Humaran I, De la Cruz-Gongora VV. Prevalence of iron deficiency was stable and anemia increased during 12 years (2006-2018) in Mexican women 20-49 years of age. Salud Publica Mex. 2021 May 3;63(3 May-Jun):401-411. doi: 10.21149/12152. Spanish. — View Citation

Moreto F, de Oliveira EP, Manda RM, Burini RC. The higher plasma malondialdehyde concentrations are determined by metabolic syndrome-related glucolipotoxicity. Oxid Med Cell Longev. 2014;2014:505368. doi: 10.1155/2014/505368. Epub 2014 Jun 24. — View Citation

Nikonorov AA, Skalnaya MG, Tinkov AA, Skalny AV. Mutual interaction between iron homeostasis and obesity pathogenesis. J Trace Elem Med Biol. 2015 Apr;30:207-14. doi: 10.1016/j.jtemb.2014.05.005. Epub 2014 May 24. — View Citation

Ross AC. Impact of chronic and acute inflammation on extra- and intracellular iron homeostasis. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1581S-1587S. doi: 10.3945/ajcn.117.155838. Epub 2017 Oct 25. — View Citation

Teng IC, Tseng SH, Aulia B, Shih CK, Bai CH, Chang JS. Can diet-induced weight loss improve iron homoeostasis in patients with obesity: A systematic review and meta-analysis. Obes Rev. 2020 Dec;21(12):e13080. doi: 10.1111/obr.13080. Epub 2020 Jul 16. — View Citation

Utami FA , Lee HC , Su CT , Guo YR , Tung YT , Huang SY . Effects of calorie restriction plus fish oil supplementation on abnormal metabolic characteristics and the iron status of middle-aged obese women. Food Funct. 2018 Feb 21;9(2):1152-1162. doi: 10.1039/c7fo01787a. — View Citation

Vela D. Hepcidin, an emerging and important player in brain iron homeostasis. J Transl Med. 2018 Feb 7;16(1):25. doi: 10.1186/s12967-018-1399-5. — View Citation

Yanoff LB, Menzie CM, Denkinger B, Sebring NG, McHugh T, Remaley AT, Yanovski JA. Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes (Lond). 2007 Sep;31(9):1412-9. doi: 10.1038/sj.ijo.0803625. Epub 2007 Apr 17. — View Citation

Zhang C, Rawal S. Dietary iron intake, iron status, and gestational diabetes. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1672S-1680S. doi: 10.3945/ajcn.117.156034. Epub 2017 Oct 25. — View Citation

Zhou Z, Zhang H, Chen K, Liu C. Iron status and obesity-related traits: A two-sample bidirectional Mendelian randomization study. Front Endocrinol (Lausanne). 2023 Feb 14;14:985338. doi: 10.3389/fendo.2023.985338. eCollection 2023. — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum hepcidin concentration in mcg/dL	Change in serum hepcidin concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum iron concentration in mcg/dL	Change in serum iron concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum ferritin concentration in ng/mL	Change in serum ferritin concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum iron binding capacity concentration in mcg/dL	Change in serum iron binding capacity concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Blood reticulocytes percentage	Change in blood reticulocytes percentage between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum soluble transferrin receptor concentration in mg/L.	Change in serum soluble transferrin receptor concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Blood haemoglobin concentration in g/dL	Change in blood haemoglobin concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum C-reactive protein concentration in g/dL	Change in C-reactive protein concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum leptin concentration in ng/mL	Change in leptin concentration in the serum determined by ELISA kit between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum interleukin 6 concentration in pg/mL	Change in interleukin-6 concentration determined by ELISA kit between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum lipopolysaccharides concentration in ng/mL	Change in lipopolysaccharides concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Plasma malondialdehyde concentration in nmol/mL	Change in malondialdehyde concentration by spectrophotometry between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Plasma trolox equivalents concentration in umols/mL	Change in trolox equivalents concentration between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Changes in faecal microbiota composition	The change in faecal microbiota composition shall be measured by 16 ribosome sequencing at baseline and at 2 months. The relative change of each bacterial taxon shall be calculated on the basis of the abundance of the given bacteria at baseline to 2 months between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum total cholesterol concentration in mg/dL	Change in total cholesterol concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum LDL cholesterol concentration in mg/dL	Change in LDL-cholesterol concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum triglycerides concentration in mg/dL	Change in triglycerides concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum aspartate aminotransferase concentration in IU/mL	Change in aspartate aminotransferase concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum alanine aminotransferase concentration in IU/mL	Change in alanine aminotransferase concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Serum glucose concentration in mg/dL	Change in serum glucose concentration determined by autoanalyzer between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Body weight in kilograms	Change in body weight between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Fat mass percentage	Change in fat mass percentage determined by multifrequency electrical bioimpedance between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Waist circumference in centimeters	Change in waist circumference between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Lean mass percentage	Change in fat mass percentage determined by multifrequency electrical bioimpedance between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention
Secondary	Skeletal muscle mass percentage	Change in fat mass percentage determined by multifrequency electrical bioimpedance between different nutritional interventions in subjects with obesity and iron deficiency	Baseline to 2 months of intervention